Skip to main content

Drug Delivery Innovation

Nanexa Secures Up to EUR 1.165B Novo Nordisk Deal for PharmaShell Tech

Nanexa Secures Up to EUR 1.165B Novo Nordisk Deal for PharmaShell Tech

Uppsala – September 25, 2026 -- Nanexa AB has signed a global exclusive license and collaboration agreement with Novo Nordisk worth up to EUR 1.165 billion, granting the Danish pharmaceutical giant rights to the Swedish company's PharmaShell atomic layer deposition (ALD) drug delivery platform for peptide-based treatments in obesity, type 2 diabetes and other cardiometabolic diseases.

Novo Nordisk gains rights to up to five development programs under the deal

The agreement covers formulations targeting monthly and quarterly administration frequencies, reducing dosing burden for chronic metabolic and cardiovascular disease patients. Novo Nordisk will lead global development and commercialization across all programs, while Nanexa retains eligibility for milestone-based payments tied to development, regulatory and sales achievements.

Nanomedicine Market to Nearly Triple to $581.2B by 2034

Nanomedicine Market to Nearly Triple to $581.2B by 2034

Pune, India – September 24, 2026 -- The global nanomedicine market reached USD 207.91 billion in 2025 and is projected to hit USD 581.2 billion by 2034, expanding at a 12.1% compound annual growth rate, according to a new report from Maximize Market Research.

North America commands the largest share on pharmaceutical R&D strength

North America held the largest share of the market in 2025, driven by advanced healthcare infrastructure, deep pharmaceutical and biotechnology research pipelines, and high healthcare expenditure. The United States anchors regional growth through its established research ecosystem and rising adoption of nanotechnology-based drug delivery, diagnostics and precision medicine platforms. Canada and Mexico are contributing through expanding healthcare capabilities and research initiatives.